<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="145938">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01200758</url>
  </required_header>
  <id_info>
    <org_study_id>BO22334</org_study_id>
    <secondary_id>2010-021377-36</secondary_id>
    <nct_id>NCT01200758</nct_id>
  </id_info>
  <brief_title>A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous (IV) in Participants With Follicular Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Two-Stage Phase III, International, Multi-Center, Randomized, Controlled, Open-Label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This two-stage, multi-center, randomized, controlled, open-label study will investigate the
      pharmacokinetics, efficacy and safety of rituximab SC versus rituximab IV in participants
      with previously untreated follicular non-Hodgkin's lymphoma. Participants will be randomized
      to receive 375 milligrams per meter square (mg/m^2) rituximab as IV infusion or 1400
      milligrams (mg) rituximab SC. In addition, participants will receive standard chemotherapy.
      Participants who achieved a complete or partial response (PR) after 8 treatment cycles, will
      receive maintenance treatment for a further maximum number of 12 cycles. Maintenance
      treatment cycles will be repeated every 8 weeks. This is a two-stage study. Stage 1 was
      designed to confirm the chosen rituximab SC dose resulting in comparable rituximab serum
      Ctrough levels compared with rituximab IV, when given as part of induction treatment every 3
      weeks. Enrollment for Stage 2 started after the rituximab SC dose was established in Stage
      1. Stage 2 aimed to further investigate the efficacy and safety of rituximab SC compared
      with rituximab IV. The anticipated time on study treatment is 96 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2011</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
    <masking_description>Open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab</measure>
    <time_frame>Stage I: Cycle (Cy) 7 Day (D) 21 (within 2 hours [hrs] predose on Cy 8) of induction treatment (1 Cy=3 weeks)</time_frame>
    <description>Number of participants = participants analyzed for this endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment</measure>
    <time_frame>Stage II: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks)</time_frame>
    <description>Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for Non-Hodgkin lymphoma (NHL). CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (&gt;) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (≥) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment</measure>
    <time_frame>Stage I and II: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks)</time_frame>
    <description>Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage I: Percentage of Participants With Overall Response at the End of Induction Treatment</measure>
    <time_frame>Stage I: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks)</time_frame>
    <description>Overall Response comprised CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in the SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I: Percentage of Participants With Complete Response at the End of Induction Treatment</measure>
    <time_frame>Stage I: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks)</time_frame>
    <description>Complete Response was comprised CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage II: Percentage of Participants With Complete Response at the End of Induction Treatment</measure>
    <time_frame>Stage II: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks)</time_frame>
    <description>Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Induction Treatment</measure>
    <time_frame>Stage I and II: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks)</time_frame>
    <description>Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Maintenance Treatment</measure>
    <time_frame>Stage I and Stage II: Baseline up to 78 days after last maintenance dose (last maintenance dose: maintenance Cy 12/Study Cy 20 [30 months] [1 Cy=8 weeks])</time_frame>
    <description>Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. Number of subjects analysed = participants evaluable for the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Maintenance Treatment</measure>
    <time_frame>Stage I and II: Baseline up to 78 days after last maintenance dose (last maintenance dose: maintenance Cy 12/Study Cy 20 [30 months] [1 Cy=8 weeks])</time_frame>
    <description>Overall Response comprised of CR, CRu, or PR . A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper. Number of subjects analysed = participants evaluable for the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 and II (Pooled): Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline, D1 of all cycles (Cy 1-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to median of 27 months;up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
    <description>PFS was defined as the time from randomization to disease progression/relapse or death due to any cause. If the specified event (disease progression/relapse, death) did not occur, PFS was censored at the last tumor assessment date showing no disease progression, either during treatment or follow-up. Disease progression was defined as progression in the participant's clinical symptoms according to the International Working Group response criteria for NHL. PFS analysis was performed using Kaplan - Meier curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Progression or Death</measure>
    <time_frame>Baseline, D1 of all cycles (Cy 1-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
    <description>Disease progression was defined as progression in the participant's clinical symptoms according to the International Working Group response criteria for NHL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I and II (Pooled): Event-Free Survival</measure>
    <time_frame>Baseline until documented disease progression/relapse or death (up to study completion [up to approximately 105 months])</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I and II (Pooled): Median Time to Overall Survival (OS)</measure>
    <time_frame>Baseline until documented disease progression/relapse or death (up to study completion [up to approximately 105 months])</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause. Participants without event were censored at the time of last follow-up information for survival (i.e., at the last time known to be alive).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1: Observed Area Under the Serum Concentration-Time Curve (AUC) of IV and SC Rituximab at Cycle 7</measure>
    <time_frame>Stage I (Induction): predose (0 hr) and 24 hrs postdose on Cy 7 (D1,3,7,15), predose (0 hr) on Cy 8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion on Cy 7 D1 for rituximab IV (up to data cutoff of 11 April 2012 [up to 26 months])</time_frame>
    <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Number of participants with evaluable PK data contributing to summary statistics were included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab at Cycle 7</measure>
    <time_frame>Stage I (Induction): predose (0 hr) and 24 hrs postdose on Cy 7 (D1,3,7,15), predose (0 hr) on Cy 8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion on Cy 7 D1 for rituximab IV (up to data cutoff of 11 April 2012 [up to 26 months])</time_frame>
    <description>Number of participants with evaluable PK data contributing to summary statistics were included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I and II (Pooled): Trough Serum Concentrations (Ctrough) of Rituximab at Each Induction Treatment Cycle</measure>
    <time_frame>Stage I and II (induction): rituximab IV - predose (0 hr) on D1 of Cy 1 to 8 (1 Cy=3 weeks and 4 weeks for Cy8); rituximab SC - predose (0 hr) on D1 of Cy 1 and Cy 3 to 8, predose (0 hr) on D0 of Cy2 (up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
    <description>n = number of participants analyzed for the endpoint at the specified timepoint. The data was provided up to data cutoff of 3 February 2014.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I and II (Pooled): Ctrough of Rituximab at Each Maintenance Treatment Cycle</measure>
    <time_frame>Stage I and II (maintenance): D29 of Cy 8 (induction; 1Cy=4 weeks), predose (0 hr) on D1 of Cy 9 to 19 (maintenance Cycle 1 to 12 [1 Cy=8 weeks]; up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
    <description>n (number) = participants analyzed in specified cycle for this endpoint. The data was provided up to data cutoff of 3 February 2014.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I and II (Pooled): Rituximab Levels 12 Weeks, 24 Weeks, and 36 Weeks After the Last Rituximab Administration</measure>
    <time_frame>12 weeks, 24 weeks, and 36 weeks after the last rituximab administration (median treatment duration: 383.5 days for IV dose and 406 days for SC dose; up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
    <description>n = number of participants analyzed for the endpoint at the specified timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With B-Cell Depletion by Cycle for Induction Phase</measure>
    <time_frame>Stage I and II (induction): for rituximab IV - D1 of Cy 1 to 8 (1 Cy=3 weeks); for rituximab SC - D1 of Cy 1 and Cy 3 to 8, D0 of Cy 2, thereafter at follow-up visits every 12 weeks after the last rituximab administration until 72 weeks</time_frame>
    <description>n = number of participants analyzed for the endpoint at the specified timepoint. The data was presented up to data cutoff of 3 February 2014.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With B-Cell Depletion by Cycle for Maintenance Phase</measure>
    <time_frame>Stage I and II (maintenance): D1 of Cy 9 to 20 (1 Cy=8 weeks) (up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
    <description>n = number of participants analyzed for the endpoint at the specified timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Chimeric Antibodies (HACAs)</measure>
    <time_frame>Baseline, Post-Baseline (Cy 1 D1 [induction] up to follow-up [1 Cy=3 weeks]) (a median of 27 months; up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
    <description>Levels of HACA in serum were collected at Day of each cycle up to Cycle 8 and at follow-up visit. n = number of participants analyzed for the endpoint at the specified timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I and II (Pooled): Percentage of Participants Who Saved Time of Staff as Per Physician/Nurse Opinions With Each Administration of Rituximab SC as Compared to Rituximab IV at the End of Cy 8, 15 and 20</measure>
    <time_frame>Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks); after 48 weeks of maintenance treatment (after Cy15) and after the end of the maintenance treatment (after Cy20) (up to data cutoff of 3 February 2014 [up to 4 year])</time_frame>
    <description>All investigator physicians and nurses involved in this study were asked to provide the staff time that could be saved with each administration of rituximab SC as compared with rituximab IV to participants in routine practice afetr Cy 8, 15, 20 and categorized as less than (&lt;) 1 hr, at least 1 hr but &lt;2 hrs, at least 2 hrs but &lt;3 hrs, at least 3 hrs but &lt;4 hrs, &gt;/=4 hrs. Staff were asked not to consider the time needed for the first IV administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage I and II (Pooled): Percentage of Participants With Preferred Rituximab SC Formulations as Compared to IV Formulation as Assessed by Physician/Nurse at the End of Cy 8, 15, and 20</measure>
    <time_frame>Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1Cy=3 weeks); after 48 weeks of maintenance treatment (after Cy15) and after the end of the maintenance treatment (after Cy20) (up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
    <description>All investigator physicians and nurses involved in this study were asked to answer the following question for convenience of rituximab SC formulation over IV formulation across all participants: Rituximab SC is much more convenient; Rituximab SC is a little more convenient; Both formulations are equally convenient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">410</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) or cyclophosphamide, vincristine, prednisolone (CVP) chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab SC</intervention_name>
    <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
    <arm_group_label>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab IV</intervention_name>
    <description>Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
    <arm_group_label>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</arm_group_label>
    <arm_group_label>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Eight cycles of cyclophosphamide (750 mg/m^2 IV) administered every 3 weeks.</description>
    <arm_group_label>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</arm_group_label>
    <arm_group_label>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Eight cycles of doxorubicin (50 mg/m^2 IV) administered every 3 weeks.</description>
    <arm_group_label>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</arm_group_label>
    <arm_group_label>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Eight cycles of doxorubicin (1.4 mg/m^2 IV) administered every 3 weeks.</description>
    <arm_group_label>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</arm_group_label>
    <arm_group_label>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone/Prednisolone</intervention_name>
    <description>Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.</description>
    <arm_group_label>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</arm_group_label>
    <arm_group_label>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cluster of differentiation 20 (CD20)-positive, follicular Non-Hodgkin's lymphoma
             grade 1, 2, 3a. A tumor biopsy must have been performed within 6 months before study
             entry with material available for central review.

          -  No prior treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

        Exclusion Criteria:

          -  Grade 3b follicular lymphoma

          -  Transformation to high-grade lymphoma secondary to follicular lymphoma

          -  Types of Non-Hodgkin's lymphoma other than follicular lymphoma

          -  Presence or history of central nervous system (CNS) disease

          -  Corticoid therapy during the last 4 weeks, except prednisone treatment less than (&lt;)
             20 milligrams per day (mg per day)

          -  Known active bacterial, viral, fungal, or mycobacterial, or any major episode of
             infections requiring hospitalization or treatment with IV antibiotics within 4 weeks
             of start of study medication, or oral antibiotics within 2 weeks prior to start of
             study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>New South Wales</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banja Luka</city>
        <zip>88000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuzla</city>
        <zip>75000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30140-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01221-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 5T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medellin-Antioquia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pereira</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Århus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33077</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Mans</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tbilisi</city>
        <zip>0177</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10707</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frechen</city>
        <zip>50226</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koeln</city>
        <zip>50674</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magedburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naunhof</city>
        <zip>04683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olpe</city>
        <zip>57462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recklinghausen</city>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saalfeld</city>
        <zip>07318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saarbruecken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Potenza</city>
        <state>Basilicata</state>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia-Romagna</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Puglia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Treviso</city>
        <state>Veneto</state>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vicenza</city>
        <state>Veneto</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ampang</city>
        <zip>68000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarawak</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Culiacan</city>
        <zip>80230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palmerston North</city>
        <zip>4442</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <zip>18</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <zip>41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan de Miraflores</city>
        <zip>Lima 29</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <zip>500326</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu-mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <zip>300079</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penza</city>
        <zip>440071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St.Petersburg, Pesochny</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <zip>812 50</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Congella</city>
        <zip>4013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kraaifontein</city>
        <zip>7570</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cádiz</city>
        <state>Cadiz</state>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adana</city>
        <zip>01120</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34300</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maidstone</city>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Romford</city>
        <zip>RM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wakefield</city>
        <zip>WF1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 23, 2017</lastchanged_date>
  <firstreceived_date>September 10, 2010</firstreceived_date>
  <firstreceived_results_date>July 7, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
          <description>Eight cycles of rituximab IV infusion (375 milligrams per square meter [mg/m^2]; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least partial response (PR) during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
        </group>
        <group group_id="P2">
          <title>Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
          <description>First cycle of rituximab IV (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
        </group>
        <group group_id="P3">
          <title>Stage II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
          <description>Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
        </group>
        <group group_id="P4">
          <title>Stage II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
          <description>First cycle of rituximab IV (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="0">Different participants were randomized into different stages of the study.</participants>
                <participants group_id="P4" count="0">Different participants were randomized into different stages of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17">Participants completed treatment period.</participants>
                <participants group_id="P2" count="16">Participants completed treatment period.</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's judgement</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing Treatment Period</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Stage 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Different participants were randomized into different stages of the study.</participants>
                <participants group_id="P2" count="0">Different participants were randomized into different stages of the study.</participants>
                <participants group_id="P3" count="141"/>
                <participants group_id="P4" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="141"/>
                <participants group_id="P4" count="142"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Judgement</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing Treatment Period</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="108"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat (ITT) Population included all participants who were randomized into study irrespective whether they received study drug or not.</population>
      <group_list>
        <group group_id="B1">
          <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
          <description>Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
        </group>
        <group group_id="B2">
          <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
          <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="205"/>
            <count group_id="B2" value="205"/>
            <count group_id="B3" value="410"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" lower_limit="28" upper_limit="86"/>
                    <measurement group_id="B2" value="56.1" lower_limit="28" upper_limit="85"/>
                    <measurement group_id="B3" value="56.5" lower_limit="28" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab</title>
        <description>Number of participants = participants analyzed for this endpoint.</description>
        <time_frame>Stage I: Cycle (Cy) 7 Day (D) 21 (within 2 hours [hrs] predose on Cy 8) of induction treatment (1 Cy=3 weeks)</time_frame>
        <population>Stage I pharmacokinetic (PK) evaluable population comprised all participants with data for Ctrough available at Cycle 7 and/or observed area under the serum concentration-time curve (AUC) available at Cycle 7. Participants were analyzed as per treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab</title>
          <description>Number of participants = participants analyzed for this endpoint.</description>
          <population>Stage I pharmacokinetic (PK) evaluable population comprised all participants with data for Ctrough available at Cycle 7 and/or observed area under the serum concentration-time curve (AUC) available at Cycle 7. Participants were analyzed as per treatment received.</population>
          <units>microgram per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" spread="36.7"/>
                    <measurement group_id="O2" value="134.6" spread="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferior Ctrough in SC formulation was demonstrated, if the lower bound of 90% confidence interval (CI) was above 0.8.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.62</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>1.94</ci_upper_limit>
            <estimate_desc>Geometric mean ratio adjusted for tumor load at baseline.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment</title>
        <description>Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for Non-Hodgkin lymphoma (NHL). CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (&gt;) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (≥) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.</description>
        <time_frame>Stage II: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment</title>
          <description>Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for Non-Hodgkin lymphoma (NHL). CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (&gt;) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (≥) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.</description>
          <population>ITT Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1" lower_limit="78.1" upper_limit="90.5"/>
                    <measurement group_id="O2" value="80.3" lower_limit="72.8" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2835</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in response rates</param_type>
            <param_value>-4.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.0</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment</title>
        <description>Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.</description>
        <time_frame>Stage I and II: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment</title>
          <description>Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.</description>
          <population>ITT Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4" lower_limit="78.7" upper_limit="89.1"/>
                    <measurement group_id="O2" value="83.4" lower_limit="77.6" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7881</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in response rates</param_type>
            <param_value>-0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>6.4</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference in response rates was estimated using the Hauck-Anderson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I: Percentage of Participants With Overall Response at the End of Induction Treatment</title>
        <description>Overall Response comprised CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in the SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.</description>
        <time_frame>Stage I: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks)</time_frame>
        <population>Stage I ITT Population included all participants who were randomized in Stage I irrespective whether they received study drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I: Percentage of Participants With Overall Response at the End of Induction Treatment</title>
          <description>Overall Response comprised CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in the SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.</description>
          <population>Stage I ITT Population included all participants who were randomized in Stage I irrespective whether they received study drug or not.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" lower_limit="71.3" upper_limit="91.1"/>
                    <measurement group_id="O2" value="90.5" lower_limit="80.4" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2047</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in response rates</param_type>
            <param_value>7.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>20.3</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I: Percentage of Participants With Complete Response at the End of Induction Treatment</title>
        <description>Complete Response was comprised CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses.</description>
        <time_frame>Stage I: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I: Percentage of Participants With Complete Response at the End of Induction Treatment</title>
          <description>Complete Response was comprised CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses.</description>
          <population>ITT Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="15.0" upper_limit="37.4"/>
                    <measurement group_id="O2" value="42.9" lower_limit="30.5" upper_limit="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0335</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in CRR</param_type>
            <param_value>17.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>35.0</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>4.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage II: Percentage of Participants With Complete Response at the End of Induction Treatment</title>
        <description>Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.</description>
        <time_frame>Stage II: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage II: Percentage of Participants With Complete Response at the End of Induction Treatment</title>
          <description>Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.</description>
          <population>ITT Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" lower_limit="26.9" upper_limit="43.2"/>
                    <measurement group_id="O2" value="28.2" lower_limit="20.9" upper_limit="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2331</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in response rates</param_type>
            <param_value>-6.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.8</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Induction Treatment</title>
        <description>Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.</description>
        <time_frame>Stage I and II: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2) in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Induction Treatment</title>
          <description>Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.</description>
          <population>ITT Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="25.4" upper_limit="38.6"/>
                    <measurement group_id="O2" value="32.7" lower_limit="26.3" upper_limit="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8326</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in response rates</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.3</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Maintenance Treatment</title>
        <description>Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. Number of subjects analysed = participants evaluable for the analysis.</description>
        <time_frame>Stage I and Stage II: Baseline up to 78 days after last maintenance dose (last maintenance dose: maintenance Cy 12/Study Cy 20 [30 months] [1 Cy=8 weeks])</time_frame>
        <population>ITT population; only participants who completed all 12 cycles of rituximab maintenance or who had withdrawn during the maintenance period were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2) in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Maintenance Treatment</title>
          <description>Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. Number of subjects analysed = participants evaluable for the analysis.</description>
          <population>ITT population; only participants who completed all 12 cycles of rituximab maintenance or who had withdrawn during the maintenance period were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="11.5" upper_limit="43.4"/>
                    <measurement group_id="O2" value="22.2" lower_limit="10.1" upper_limit="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7875</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in response rates</param_type>
            <param_value>-2.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.9</ci_lower_limit>
            <ci_upper_limit>19.3</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Maintenance Treatment</title>
        <description>Overall Response comprised of CR, CRu, or PR . A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper. Number of subjects analysed = participants evaluable for the analysis.</description>
        <time_frame>Stage I and II: Baseline up to 78 days after last maintenance dose (last maintenance dose: maintenance Cy 12/Study Cy 20 [30 months] [1 Cy=8 weeks])</time_frame>
        <population>ITT population; only participants who completed all 12 cycles of rituximab maintenance or who had withdrawn during the maintenance period were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2) in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Maintenance Treatment</title>
          <description>Overall Response comprised of CR, CRu, or PR . A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by &gt;75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper. Number of subjects analysed = participants evaluable for the analysis.</description>
          <population>ITT population; only participants who completed all 12 cycles of rituximab maintenance or who had withdrawn during the maintenance period were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" lower_limit="26.4" upper_limit="62.3"/>
                    <measurement group_id="O2" value="44.4" lower_limit="27.9" upper_limit="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9541</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in response rates</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.9</ci_lower_limit>
            <ci_upper_limit>26.3</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 1 and II (Pooled): Progression-Free Survival (PFS)</title>
        <description>PFS was defined as the time from randomization to disease progression/relapse or death due to any cause. If the specified event (disease progression/relapse, death) did not occur, PFS was censored at the last tumor assessment date showing no disease progression, either during treatment or follow-up. Disease progression was defined as progression in the participant's clinical symptoms according to the International Working Group response criteria for NHL. PFS analysis was performed using Kaplan – Meier curves.</description>
        <time_frame>Baseline, D1 of all cycles (Cy 1-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to median of 27 months;up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2) in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1 and II (Pooled): Progression-Free Survival (PFS)</title>
          <description>PFS was defined as the time from randomization to disease progression/relapse or death due to any cause. If the specified event (disease progression/relapse, death) did not occur, PFS was censored at the last tumor assessment date showing no disease progression, either during treatment or follow-up. Disease progression was defined as progression in the participant's clinical symptoms according to the International Working Group response criteria for NHL. PFS analysis was performed using Kaplan – Meier curves.</description>
          <population>ITT Population.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data for median and corresponding 95% CI were not reached due to low number (&lt;50%) of participants with event of interest.</measurement>
                    <measurement group_id="O2" value="NA">Data for median and corresponding 95% CI were not reached due to low number (&lt;50%) of participants with event of interest.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4646</p_value>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Disease Progression or Death</title>
        <description>Disease progression was defined as progression in the participant's clinical symptoms according to the International Working Group response criteria for NHL.</description>
        <time_frame>Baseline, D1 of all cycles (Cy 1-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2) in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease Progression or Death</title>
          <description>Disease progression was defined as progression in the participant's clinical symptoms according to the International Working Group response criteria for NHL.</description>
          <population>ITT Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                    <measurement group_id="O2" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I and II (Pooled): Event-Free Survival</title>
        <time_frame>Baseline until documented disease progression/relapse or death (up to study completion [up to approximately 105 months])</time_frame>
        <posting_date>11/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I and II (Pooled): Median Time to Overall Survival (OS)</title>
        <description>OS was defined as the time from randomization to death due to any cause. Participants without event were censored at the time of last follow-up information for survival (i.e., at the last time known to be alive).</description>
        <time_frame>Baseline until documented disease progression/relapse or death (up to study completion [up to approximately 105 months])</time_frame>
        <posting_date>11/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 1: Observed Area Under the Serum Concentration-Time Curve (AUC) of IV and SC Rituximab at Cycle 7</title>
        <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Number of participants with evaluable PK data contributing to summary statistics were included.</description>
        <time_frame>Stage I (Induction): predose (0 hr) and 24 hrs postdose on Cy 7 (D1,3,7,15), predose (0 hr) on Cy 8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion on Cy 7 D1 for rituximab IV (up to data cutoff of 11 April 2012 [up to 26 months])</time_frame>
        <population>PK evaluable population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Observed Area Under the Serum Concentration-Time Curve (AUC) of IV and SC Rituximab at Cycle 7</title>
          <description>AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Number of participants with evaluable PK data contributing to summary statistics were included.</description>
          <population>PK evaluable population.</population>
          <units>µg.day/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2734.21" spread="32.51"/>
                    <measurement group_id="O2" value="3778.93" spread="37.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The ratio of observed rituximab serum was determined as AUCSC/AUCIV during Cycle 7 of induction treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.378</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.241</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab at Cycle 7</title>
        <description>Number of participants with evaluable PK data contributing to summary statistics were included.</description>
        <time_frame>Stage I (Induction): predose (0 hr) and 24 hrs postdose on Cy 7 (D1,3,7,15), predose (0 hr) on Cy 8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion on Cy 7 D1 for rituximab IV (up to data cutoff of 11 April 2012 [up to 26 months])</time_frame>
        <population>Stage 1 PK Evaluable Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle of rituximab IV (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab at Cycle 7</title>
          <description>Number of participants with evaluable PK data contributing to summary statistics were included.</description>
          <population>Stage 1 PK Evaluable Population.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.63" spread="19.66"/>
                    <measurement group_id="O2" value="236.82" spread="31.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I and II (Pooled): Trough Serum Concentrations (Ctrough) of Rituximab at Each Induction Treatment Cycle</title>
        <description>n = number of participants analyzed for the endpoint at the specified timepoint. The data was provided up to data cutoff of 3 February 2014.</description>
        <time_frame>Stage I and II (induction): rituximab IV - predose (0 hr) on D1 of Cy 1 to 8 (1 Cy=3 weeks and 4 weeks for Cy8); rituximab SC - predose (0 hr) on D1 of Cy 1 and Cy 3 to 8, predose (0 hr) on D0 of Cy2 (up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2) in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I and II (Pooled): Trough Serum Concentrations (Ctrough) of Rituximab at Each Induction Treatment Cycle</title>
          <description>n = number of participants analyzed for the endpoint at the specified timepoint. The data was provided up to data cutoff of 3 February 2014.</description>
          <population>ITT Population.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 (n = 198, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" spread="157.53"/>
                    <measurement group_id="O2" value="12.88" spread="189.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 (n = 197, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.13" spread="145.36"/>
                    <measurement group_id="O2" value="40.00" spread="124.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 (n = 192, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.25" spread="110.35"/>
                    <measurement group_id="O2" value="63.83" spread="101.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 (n = 186, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.06" spread="108.90"/>
                    <measurement group_id="O2" value="81.71" spread="92.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 (n = 185, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.68" spread="89.90"/>
                    <measurement group_id="O2" value="98.00" spread="71.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 (n = 187, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.02" spread="87.60"/>
                    <measurement group_id="O2" value="109.56" spread="58.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 (n = 183, 172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.31" spread="77.76"/>
                    <measurement group_id="O2" value="120.75" spread="55.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 (n = 52, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.60" spread="70.53"/>
                    <measurement group_id="O2" value="131.48" spread="50.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I and II (Pooled): Ctrough of Rituximab at Each Maintenance Treatment Cycle</title>
        <description>n (number) = participants analyzed in specified cycle for this endpoint. The data was provided up to data cutoff of 3 February 2014.</description>
        <time_frame>Stage I and II (maintenance): D29 of Cy 8 (induction; 1Cy=4 weeks), predose (0 hr) on D1 of Cy 9 to 19 (maintenance Cycle 1 to 12 [1 Cy=8 weeks]; up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2) in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I and II (Pooled): Ctrough of Rituximab at Each Maintenance Treatment Cycle</title>
          <description>n (number) = participants analyzed in specified cycle for this endpoint. The data was provided up to data cutoff of 3 February 2014.</description>
          <population>ITT Population.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 8 (n = 156, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.54" spread="97.10"/>
                    <measurement group_id="O2" value="62.08" spread="67.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 (n = 142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.27" spread="73.85"/>
                    <measurement group_id="O2" value="48.26" spread="83.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 (n = 105, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.66" spread="78.63"/>
                    <measurement group_id="O2" value="44.65" spread="78.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 (n = 78, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.15" spread="71.27"/>
                    <measurement group_id="O2" value="44.65" spread="66.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 (n = 61, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.12" spread="59.19"/>
                    <measurement group_id="O2" value="45.70" spread="67.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 (n = 49, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.33" spread="52.03"/>
                    <measurement group_id="O2" value="45.52" spread="67.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 (n = 47, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.18" spread="44.80"/>
                    <measurement group_id="O2" value="45.54" spread="65.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 (n = 43, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.45" spread="35.36"/>
                    <measurement group_id="O2" value="45.16" spread="69.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 (n = 45, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.36" spread="44.00"/>
                    <measurement group_id="O2" value="44.09" spread="65.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 (n = 42, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.50" spread="43.97"/>
                    <measurement group_id="O2" value="42.96" spread="63.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 (n = 29, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.29" spread="39.15"/>
                    <measurement group_id="O2" value="49.11" spread="56.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 (n = 17, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.10" spread="36.91"/>
                    <measurement group_id="O2" value="44.99" spread="61.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I and II (Pooled): Rituximab Levels 12 Weeks, 24 Weeks, and 36 Weeks After the Last Rituximab Administration</title>
        <description>n = number of participants analyzed for the endpoint at the specified timepoint.</description>
        <time_frame>12 weeks, 24 weeks, and 36 weeks after the last rituximab administration (median treatment duration: 383.5 days for IV dose and 406 days for SC dose; up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
        <population>Safety Analysis Population included all participants who received at least one dose of rituximab, either IV or SC. Participants were analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2) in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I and II (Pooled): Rituximab Levels 12 Weeks, 24 Weeks, and 36 Weeks After the Last Rituximab Administration</title>
          <description>n = number of participants analyzed for the endpoint at the specified timepoint.</description>
          <population>Safety Analysis Population included all participants who received at least one dose of rituximab, either IV or SC. Participants were analyzed as treated.</population>
          <units>µg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12: Follow-up Visit 1 (n = 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.00" lower_limit="4.76" upper_limit="80.40"/>
                    <measurement group_id="O2" value="29.35" lower_limit="24.10" upper_limit="50.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Follow-up Visit 2 (n = 2, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" lower_limit="1.25" upper_limit="8.81"/>
                    <measurement group_id="O2" value="10.40" lower_limit="3.31" upper_limit="62.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: Follow-up Visit 3 (n = 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.22" lower_limit="1.03" upper_limit="51.4"/>
                    <measurement group_id="O2" value="8.93" lower_limit="8.93" upper_limit="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With B-Cell Depletion by Cycle for Induction Phase</title>
        <description>n = number of participants analyzed for the endpoint at the specified timepoint. The data was presented up to data cutoff of 3 February 2014.</description>
        <time_frame>Stage I and II (induction): for rituximab IV - D1 of Cy 1 to 8 (1 Cy=3 weeks); for rituximab SC - D1 of Cy 1 and Cy 3 to 8, D0 of Cy 2, thereafter at follow-up visits every 12 weeks after the last rituximab administration until 72 weeks</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2) in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With B-Cell Depletion by Cycle for Induction Phase</title>
          <description>n = number of participants analyzed for the endpoint at the specified timepoint. The data was presented up to data cutoff of 3 February 2014.</description>
          <population>ITT Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1 - Baseline (n=188, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6"/>
                    <measurement group_id="O2" value="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 0/1 (n=183, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1"/>
                    <measurement group_id="O2" value="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1 (n=175, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=178, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1 (n=179, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1 (n=173, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1 (n=178, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1 (n=175, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 19 Final Assessment (n=151, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Follow-up Visit 1 (n=20, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Follow-up Visit 2 (n=10, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: Follow-up Visit 3 (n=3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Follow-up Visit 4 (n=3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: Follow-up Visit 5 (n=1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: Follow-up Visit 6 (n=1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With B-Cell Depletion by Cycle for Maintenance Phase</title>
        <description>n = number of participants analyzed for the endpoint at the specified timepoint.</description>
        <time_frame>Stage I and II (maintenance): D1 of Cy 9 to 20 (1 Cy=8 weeks) (up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2) in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With B-Cell Depletion by Cycle for Maintenance Phase</title>
          <description>n = number of participants analyzed for the endpoint at the specified timepoint.</description>
          <population>ITT Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 9 Day 1 (n=169, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1 (n=158, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1 (n=130, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1 (n=106, 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1 (n=79, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1 (n=62, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1 (n=47, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1 (n=45, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1 (n=45, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1 (n=43, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1 (n=45, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1 (n=31, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Chimeric Antibodies (HACAs)</title>
        <description>Levels of HACA in serum were collected at Day of each cycle up to Cycle 8 and at follow-up visit. n = number of participants analyzed for the endpoint at the specified timepoint.</description>
        <time_frame>Baseline, Post-Baseline (Cy 1 D1 [induction] up to follow-up [1 Cy=3 weeks]) (a median of 27 months; up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
        <population>Safety Analysis Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
            <description>Eight cycles of rituximab IV infusion (375 mg/m^2) in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Chimeric Antibodies (HACAs)</title>
          <description>Levels of HACA in serum were collected at Day of each cycle up to Cycle 8 and at follow-up visit. n = number of participants analyzed for the endpoint at the specified timepoint.</description>
          <population>Safety Analysis Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=207, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline (n=206, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I and II (Pooled): Percentage of Participants Who Saved Time of Staff as Per Physician/Nurse Opinions With Each Administration of Rituximab SC as Compared to Rituximab IV at the End of Cy 8, 15 and 20</title>
        <description>All investigator physicians and nurses involved in this study were asked to provide the staff time that could be saved with each administration of rituximab SC as compared with rituximab IV to participants in routine practice afetr Cy 8, 15, 20 and categorized as less than (&lt;) 1 hr, at least 1 hr but &lt;2 hrs, at least 2 hrs but &lt;3 hrs, at least 3 hrs but &lt;4 hrs, &gt;/=4 hrs. Staff were asked not to consider the time needed for the first IV administration.</description>
        <time_frame>Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks); after 48 weeks of maintenance treatment (after Cy15) and after the end of the maintenance treatment (after Cy20) (up to data cutoff of 3 February 2014 [up to 4 year])</time_frame>
        <population>ITT Population. Number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I and II (Pooled): Percentage of Participants Who Saved Time of Staff as Per Physician/Nurse Opinions With Each Administration of Rituximab SC as Compared to Rituximab IV at the End of Cy 8, 15 and 20</title>
          <description>All investigator physicians and nurses involved in this study were asked to provide the staff time that could be saved with each administration of rituximab SC as compared with rituximab IV to participants in routine practice afetr Cy 8, 15, 20 and categorized as less than (&lt;) 1 hr, at least 1 hr but &lt;2 hrs, at least 2 hrs but &lt;3 hrs, at least 3 hrs but &lt;4 hrs, &gt;/=4 hrs. Staff were asked not to consider the time needed for the first IV administration.</description>
          <population>ITT Population. Number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After Cy 8: &lt;1 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 8: At least 1 hr but &lt;2 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 8: At least 2 hrs but &lt;3 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 8: At least 3 hrs but &lt;4 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 8: &gt;/=4 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 15: &lt;1 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 15: At least 1 hr but &lt;2 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 15: At least 2 hrs but &lt;3 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 15: At least 3 hrs but &lt;4 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 15: &gt;/=4 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 20: &lt;1 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 20: At least 1 hr but &lt;2 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 20: At least 2 hrs but &lt;3 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 20: At least 3 hrs but &lt;4 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy 20: &gt;/=4 hrs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage I and II (Pooled): Percentage of Participants With Preferred Rituximab SC Formulations as Compared to IV Formulation as Assessed by Physician/Nurse at the End of Cy 8, 15, and 20</title>
        <description>All investigator physicians and nurses involved in this study were asked to answer the following question for convenience of rituximab SC formulation over IV formulation across all participants: Rituximab SC is much more convenient; Rituximab SC is a little more convenient; Both formulations are equally convenient.</description>
        <time_frame>Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1Cy=3 weeks); after 48 weeks of maintenance treatment (after Cy15) and after the end of the maintenance treatment (after Cy20) (up to data cutoff of 3 February 2014 [up to 4 years])</time_frame>
        <population>ITT Population. Number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
            <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage I and II (Pooled): Percentage of Participants With Preferred Rituximab SC Formulations as Compared to IV Formulation as Assessed by Physician/Nurse at the End of Cy 8, 15, and 20</title>
          <description>All investigator physicians and nurses involved in this study were asked to answer the following question for convenience of rituximab SC formulation over IV formulation across all participants: Rituximab SC is much more convenient; Rituximab SC is a little more convenient; Both formulations are equally convenient.</description>
          <population>ITT Population. Number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After Cy8: Rituximab SC is more convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy8: Rituximab SC is little more convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy8: Both formulation are equally convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy8: Rituximab IV is little more convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy8: Rituximab IV is much more convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy15: Rituximab SC is more convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy15: Rituximab SC is ittle More convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy15:Both formulation are equally convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy15: Rituximab IV is little more convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy15: Rituximab IV is much more convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy20: Rituximab SC is more convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy20: Rituximab SC is ittle More convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy20:Both formulation are equally convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy20: Rituximab IV is little more convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Cy20: Rituximab IV is much more convenient</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Other adverse event (AE): up to 28 days after last treatment (up to 31 months). Treatment-emergent serious AE (SAEs): up to 1 year after last treatment of study drug (up to 42 months). Treatment-related SAEs: up to the end of the study (up to 91 months).</time_frame>
      <desc>Safety Population included all participants who received at least one dose of rituximab, either IV or SC. Participants were analyzed as treated.</desc>
      <group_list>
        <group group_id="E1">
          <title>Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)</title>
          <description>Eight cycles of rituximab IV infusion (375 mg/m^2) in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.</description>
        </group>
        <group group_id="E2">
          <title>Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)</title>
          <description>First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Oral lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Proctocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Bacterial prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Creutzfeldt-Jacob disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Eastern Cooperative Oncology Group performance status worsened</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Coma hepatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Musle spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-LaRoche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
